Could BP plc, HSBC Holdings plc & GlaxoSmithKline plc Be Next To Cut Their Dividends?

Are the 5%+ yields from BP plc (LON:BP), HSBC Holdings plc (LON:HSBA) & GlaxoSmithKline plc (LON:GSK) too good to be true?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Income investors are feeling the squeeze as almost a fifth of all FTSE 100 companies have announced dividend cuts over the past year or so. Even companies which have previously been considered as safe and reliable investments, such as Tesco, Centrica and Severn Trent, were unable to maintain their dividend payouts after reporting sharp declines in earnings. And so far into 2016, 3 high profile dividend cuts have already been made, namely BHP Billiton, Rio Tinto and Barclays.

Here are 3 high yielding blue-chip stocks that could be next to cut their dividends:

Perilous

BP‘s (LSE: BP) earnings, which more than halved in 2015, are putting its 7.4% dividend yield in perilous territory. Underlying earnings covered just 80% of its dividend in 2015, but what’s worse is the company’s free cash flow position.

The company’s $18.6bn capex budget in 2015 was only just about covered by operating cash flow of $19.1bn, leaving an overwhelming majority of its $6.7bn dividend funded by new borrowings. The rapid growth in net debt, which rose 20% in 2015 alone and totalled $27.2 billion at the end of the year, demonstrates that with current oil prices, its existing dividend policy is unsustainable.

BP cannot afford to wait for oil prices to recover, and should act quickly to protect its balance sheet by cutting dividends soon. Oil prices do not seem to have much further to fall, but they are unlikely to bounce back any time soon. The shale revolution in North America has changed the dynamics of the energy market for good, and so the lower oil price environment appears to be the new normal.

BP’s dividend futures, which are exchange traded derivative contracts that allows investors to take positions on future dividend payments, are pricing in a 17% dividend cut in 2016, which indicates just a modest probability of a dividend cut this year. But for 2017, BP faces a bigger risk of a dividend cut, with a 40% dividend cut being priced in by the markets.

Risky

Over the past year, two UK banks – Standard Chartered and Barclays – have come to announce big dividend cuts, following weaker than expected earnings and increased restructuring costs. HSBC (LSE: HSBA), which has long been suffering from weak profitability, could be the next bank to cut its dividend.

Earnings per share (EPS) for the bank have fallen year-on-year for the past two consecutive years now, from $0.84 in 2013, to $0.65 in 2015,  whilst dividends per share have increased from $0.49 to $0.51 over the same period. This meant dividend cover has fallen from over 1.7x, to currently less than 1.3x.

HSBC’s dividend futures are pointing to a 10% and a 18% cut in its dividend in 2016 and 2017, respectively, which puts the bank at a substantially lower risk of dividend cuts. But, with uncertainties coming from slowing growth in emerging markets and a negative earnings trend, HSBC’s shares still appear to be a risky income investment.

Positive

GlaxoSmithKline (LSE: GSK) is the least cyclical of the three stocks mentioned here, which should also mean it is the safest. However, recent patent expirations for its major blockbuster drugs and intense competition from generic manufacturers have had a serious impact on revenues and earnings.

As a result of weak earnings, GSK has frozen its dividend at 80 pence per share for each year until 2018. But, despite the dividend freeze, GSK is unable to fully cover its dividend. A 15% drop in core EPS in 2015 caused its dividend cover to fall to just beneath the 1.0x mark in 2015.

Fortunately, for the drug company, the longer-term outlook is more positive. GSK benefits from an impressive pipeline of 40 new drugs, and already green shoots of recovery are becoming visible. New products accounted for £2 billion of sales in 2015, with signs of strong quarter-on-quarter growth rates. Looking forward, GSK expects £6 billion of sales will come from these new products by 2018, offsetting much of the impact of expiring blockbusters.

Jack Tang has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline and HSBC Holdings. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

A 6.3% forecast yield! 1 bargain-basement FTSE passive income gem to buy today?  

This FTSE 100 passive income star has delivered consistently high dividends, with analysts forecasting more to come, and it looks…

Read more »

British coins and bank notes scattered on a surface
Investing Articles

£100 invested in a Stocks and Shares ISA today could be worth…

A Stocks and Shares ISA is a proven way of building wealth. But how much could a smaller stake of…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

April opportunities: 2 heavily-discounted stocks to consider buying

Are under-the-radar growth stocks the best place to look for potential stocks to buy as investors look for certainty in…

Read more »

Workers at Whiting refinery, US
Investing Articles

Why the BP share price *finally* surged 24.5% in March

Long-term owners of BP stock have had a frustrating few years, but is the share price rising 24.5% in March…

Read more »

Night Takeoff Of The American Space Shuttle
Investing For Beginners

Why April could be the start of a stock market recovery

Jon Smith lays out the blueprint of different catalysts that could lead to April being a solid month for a…

Read more »

Typical street lined with terraced houses and parked cars
Investing Articles

This FTSE 100 stock has fallen 50% and directors are loading up on shares

This FTSE 100 name has crashed spectacularly and company directors are snapping up shares. Clearly, these insiders expect it to…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

I like Rolls-Royce shares but not the price tag. Here are 2 cheaper alternatives

Rolls-Royce is an incredible company but its shares are richly valued. So are there alternative stocks offering exposure to its…

Read more »

Young Caucasian man making doubtful face at camera
Investing Articles

Should I buy Lloyds shares before the ISA deadline?

Dr James Fox takes a closer look at Lloyds' shares with the Stocks and Shares ISA deadline fast approaching. The…

Read more »